India, Aug. 3 -- Biocon Ltd. has announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea® 2 mg used to treat various retinal and ophthalmic disorders.
The product received U.S. FDA approval with interchangeable designation in May 2024, allowing pharmacists to substitute it for the reference product in accordance with state regulations.
The launch strengthens Biocon's presence in the ophthalmology segment and expands patient access to more affordable treatment options. The reference drug, Eylea, generated approximately USD 5.89 billion in U.S. sales in 2023, highlighting the significant market opportunity for the biosimilar.
Published by HT Digital Content Services ...